KR20200089666A - Alk7 결합 단백질 및 그의 용도 - Google Patents

Alk7 결합 단백질 및 그의 용도 Download PDF

Info

Publication number
KR20200089666A
KR20200089666A KR1020207013832A KR20207013832A KR20200089666A KR 20200089666 A KR20200089666 A KR 20200089666A KR 1020207013832 A KR1020207013832 A KR 1020207013832A KR 20207013832 A KR20207013832 A KR 20207013832A KR 20200089666 A KR20200089666 A KR 20200089666A
Authority
KR
South Korea
Prior art keywords
seq
alk7
amino acid
acid sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207013832A
Other languages
English (en)
Korean (ko)
Inventor
라빈드라 쿠마
로즐린 캐스톤과이
다이엔 사코
조나단 벨크
나단 제이. 샤키
Original Assignee
악셀레론 파마 인코포레이티드
아디맵 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 악셀레론 파마 인코포레이티드, 아디맵 엘엘씨 filed Critical 악셀레론 파마 인코포레이티드
Publication of KR20200089666A publication Critical patent/KR20200089666A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020207013832A 2017-10-25 2018-10-25 Alk7 결합 단백질 및 그의 용도 Ceased KR20200089666A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577038P 2017-10-25 2017-10-25
US62/577,038 2017-10-25
PCT/US2018/057482 WO2019084249A1 (en) 2017-10-25 2018-10-25 ALK7 BINDING PROTEINS AND USES THEREOF

Publications (1)

Publication Number Publication Date
KR20200089666A true KR20200089666A (ko) 2020-07-27

Family

ID=66246796

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207013832A Ceased KR20200089666A (ko) 2017-10-25 2018-10-25 Alk7 결합 단백질 및 그의 용도

Country Status (9)

Country Link
US (2) US11981738B2 (enExample)
EP (1) EP3700571A4 (enExample)
JP (2) JP7433222B2 (enExample)
KR (1) KR20200089666A (enExample)
CN (1) CN111836642A (enExample)
AU (1) AU2018354295B2 (enExample)
BR (1) BR112020007751A2 (enExample)
CA (1) CA3079963A1 (enExample)
WO (1) WO2019084249A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501547B2 (en) 2016-04-22 2019-12-10 Acceleron Pharma Inc. ALK7 binding proteins and uses thereof
CA3079963A1 (en) 2017-10-25 2019-05-02 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof
AU2020282764A1 (en) * 2019-05-30 2021-12-02 Acceleron Pharma Inc. ALK7 binding proteins and uses thereof
JP7541709B2 (ja) * 2020-03-19 2024-08-29 株式会社CUBICStars タンパク質結合部位情報取得装置、タンパク質結合部位情報取得装置の作動方法及びプログラム

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
JP2001513652A (ja) 1997-06-06 2001-09-04 アサト アクチエンゲゼルシャフト アプライド サイエンス アンド テクノロジー 抗−ｇｐｉｉｂ／ｉｉｉａ組み換え抗体
AR055191A1 (es) 2005-10-12 2007-08-08 Morphosys Ag Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
CA2896413A1 (en) 2008-12-05 2010-06-10 Abraxis Bioscience Llc Sparc binding peptides and uses thereof
AU2014368474A1 (en) 2013-12-19 2016-06-16 Arsanis Biosciences Gmbh Antibodies directed against the LukGH (LukAB) toxin of Staphylococcus aureus and antibody sequences
KR101644043B1 (ko) 2014-03-18 2016-08-01 한국과학기술원 Ｒｎａ에 특이적으로 결합하는 항체
US20170306027A1 (en) * 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
US10501547B2 (en) 2016-04-22 2019-12-10 Acceleron Pharma Inc. ALK7 binding proteins and uses thereof
CA3079963A1 (en) 2017-10-25 2019-05-02 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof

Also Published As

Publication number Publication date
EP3700571A4 (en) 2021-07-28
CA3079963A1 (en) 2019-05-02
JP2024023278A (ja) 2024-02-21
US11981738B2 (en) 2024-05-14
BR112020007751A2 (pt) 2020-10-20
AU2018354295A1 (en) 2020-04-30
JP7433222B2 (ja) 2024-02-19
CN111836642A (zh) 2020-10-27
JP2021500895A (ja) 2021-01-14
US20200392233A1 (en) 2020-12-17
WO2019084249A1 (en) 2019-05-02
EP3700571A1 (en) 2020-09-02
AU2018354295B2 (en) 2025-08-14
US20240287196A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
AU2021227687B2 (en) Antibodies against SARS-CoV-2 and methods of using the same
KR102330653B1 (ko) Il-18 결합 분자
KR102405278B1 (ko) Alk7 결합 단백질 및 이들의 용도
KR20190133160A (ko) 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
JP2024023278A (ja) Ａｌｋ７結合タンパク質およびその使用
KR20180072821A (ko) Pd-1과 특이적으로 결합하는 항체 및 그의 용도
KR20100075559A (ko) 헤파린-결합 표피 성장 인자-유사 성장 인자 항원 결합 단백질
KR20220016802A (ko) 항-nme 항체 및 암 또는 암 전이의 치료 방법
KR20160131073A (ko) Lg4-5에 대해 특이적인 항-라미닌4 항체
KR20230028796A (ko) 항-nme 항체 및 암 또는 암 전이의 치료 방법
KR20230021699A (ko) 항-nme 항체 및 암 또는 암 전이의 치료 방법
US12365736B2 (en) ALK7 binding proteins and uses thereof
KR20220063235A (ko) Entpd2 항체 및 cd73 항체의 병용 요법
RU2790991C2 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
HK40003020B (en) Alk7 binding proteins and uses thereof
HK40003020A (en) Alk7 binding proteins and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200514

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211025

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240626

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D